CyclASol topical ocular, eye drops

DRUG2 trials

Sponsors

Novaliq GmbH

Conditions

Dry Eye Disease

Phase 2

CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

CompletedNCT03292809

Novaliq GmbHDry Eye Disease

Start: 2017-10-19End: 2018-06-20Updated: 2022-12-22

Phase 3

ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

CompletedNCT04523129

Novaliq GmbHDry Eye Disease

Start: 2020-12-05End: 2021-10-08Updated: 2023-03-10

Related Papers

Pooled results from two pivotal randomized controlled clinical trials: ESSENCE-1 and ESSENCE-2 to assess efficacy and safety of a water-free ciclosporin 0.1% formulation for the treatment of dry eye disease.

2024-11-284 citations

Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease

JAMA Ophthalmology2023-04-0661 citations